Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach.

Cesano, Alessandra; Visonneau, Sophie; Cioé, Livia; Clark, Steven C.; Rovera, Giovanni; Santoli, Daniela

doi:10.1172/jci117422

Cited by 31 publications

(21 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first successful report of engraftment of hu-AML into SCID recipients was reported in 1991 (De Lord et al, 1991). Because of innate host resistance and lacking species cross reactivity in cytokines, consequent studies (De Lord et al, 1991;Cesano et al, 1992;Ratajczak et al, 1992;Namikawa et al, 1993;Cesano et al, 1994;Chelstrom et al, 1994;Lapidot et al, 1994;Pirruccello et al, 1994;Yan et al, 1996) were eclipsed by major practical and limiting considerations. While giving exogenous human growth factors, including interleukin 3 (IL-3) (Goan et al, 1995;Cashman et al, 1997), IL-6 (Goan et al, 1995), granulocyte-macrophage-colony stimulating factor (GM-CSF) (Goan et al, 1995;Cashman et al, 1997), a fusion protein of IL-3 and GM-CSF (PIXY321) (Lapidot et al, 1992;Lapidot et al, 1994), steel factor (SF) (Cashman et al, 1997), mast-cell growth factor (hMGF) (Lapidot et al, 1994) and erythropoietin (EPO) (Cashman et al, 1997) to these recipients, resulted in enhanced engraftment and differentiation of human cells in SCID recipients.…”

Section: Scid Modelsmentioning

confidence: 99%

“…The dose of total body irradiation (TBI) depended on the mouse strains and also on the source and irradiator. It usually varied from 2 Gy to 4Gy (Chelstrom et al, 1994;Tavor et al, 2004;Liu et al, 2007;Sanchez et al, 2009). Mice should be kept in a specific pathogenfree environment with acidified water at least one week before receiving pretreatment.…”

Section: Xenogeneic Transplantation and Assessment Of Engraftmentmentioning

confidence: 99%

See 1 more Smart Citation

How to Establish Acute Myeloid Leukemia Xenograft Models Using Immunodeficient Mice

Shan

Ma²

2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The discovery of the immunodeficient mice has provided a tool for establishing animal models as hosts for in vivo analysis of AML. Various model systems have been established in the last few decades, and it is essential that murine AML models are developed to exploit more specific, targeted therapeutics. In this review, we concentrate on the models of AML and discuss the development of immunodeficiency models for understanding of leukemogenesis, describe those now available and their values and document the methods used for establishing and identifying AML mice models, as well as factors influencing engraftment of human AML in immunodeficient mice. Thus, the function of this article is to provide clinicians and experimentalists with a chronological, comprehensive appraisal of all AML model systems. Keywords: SCID -NOD/SCID -acute myeloid leukemia (AML) -model MINI-REVIEW How to Establish Acute Myeloid Leukemia Xenograft Models Using Immunodeficient MiceWu-Lin Shan 1,2 , Xiao-Ling Ma 1,2 * patients. Despite intensive effort from many laboratories around the world, none of the existing models was ideal. Considerable progress has been made by using a variety of complementary approaches. This review will emphasize the advantages and drawbacks of the human AML models established by using immunodeficient mice.

show abstract

Section: Scid Modelsmentioning

confidence: 99%

Section: Xenogeneic Transplantation and Assessment Of Engraftmentmentioning

confidence: 99%

How to Establish Acute Myeloid Leukemia Xenograft Models Using Immunodeficient Mice

Shan

Ma²

2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…[327][328][329][330][331][332][333] The first successful report of human stem cell engraftment into a scid mouse was reported in 1988 316 following transplantation of human foetal tissues with subsequent engraftment of hu-AML into scid recipients in 1991. 334 Consequent studies 280,[334][335][336][337][338][339][340][341][342] resulted in the inchoate identification of the CD34 þ CD38 À scid leukaemia initiating cell (SL-IC) 335,343 whose phenotype is similar to normal HSCs, and the finding that AMLs of differing FAB classifications which engrafted in scid recipients faithfully recapitulated their intrinsic pathological and clinically observed disparities. 335,339 The significance of these results was eclipsed by major practical and limiting considerations.…”

Section: Nude Modelsmentioning

confidence: 99%

Animal models of acute myelogenous leukaemia – development, application and future perspectives

2005

View full text Add to dashboard Cite

From the early inception of the transplant models through to contemporary genetic and xenograft models, evolution of murine leukaemic model systems have been critical to our general comprehension and treatment of cancer, and, more specifically, disease states such as acute myelogenous leukaemia (AML). However, even with modern advances in therapeutics and molecular diagnostics, the majority of AML patients die from their disease. Thus, in the absence of definitive in vitro models which precisely recapitulate the in vivo setting of human AMLs and failure of significant numbers of new drugs late in clinical trials, it is essential that murine AML models are developed to exploit more specific, targeted therapeutics. While various model systems are described and discussed in the literature from initial transplant models such as BNML and spontaneous murine leukaemia virus models, to the more definitive genetic and clinically significant NOD/SCID xenograft models, there exists no single compendium which directly assesses, reviews or compares the relevance of these models. Thus, the function of this article is to provide clinicians and experimentalists a chronological, comprehensive appraisal of all AML model systems, critical discussion on the elucidation of their roles in our understanding of AML and consideration to their efficacy in the development of AML chemotherapeutics.

show abstract

“…[13][14][15] Conditioning of SCID cells into severe combined immunodeficient (SCID) mice mice using sublethal TBI and intravenous transplantation allows for evaluation of long-term growth abilities of these cells allows for outgrowth of these cells in the SCID mouse bone…”

Section: Transplantation Of Normal and Malignant Human Hematopoieticmentioning

confidence: 99%

Facilitated engraftment of human hematopoietic cells in severe combined immunodeficient mice following a single injection of Cl2MDP liposomes

et al. 1997

View full text Add to dashboard Cite

Transplantation of normal and malignant human hematopoietictherapeutic interventions in vivo. [13][14][15] Conditioning of SCID cells into severe combined immunodeficient (SCID) mice mice using sublethal TBI and intravenous transplantation allows for evaluation of long-term growth abilities of these cells allows for outgrowth of these cells in the SCID mouse boneand provides a preclinical model for therapeutic interventions.marrow. 1,16However, large numbers of cells are required for successful However, even following sublethal irradiation of SCID mice somes which contain clodronate (Cl 2 MDP). Such liposomes

show abstract

Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach.

Cited by 31 publications

References 28 publications

How to Establish Acute Myeloid Leukemia Xenograft Models Using Immunodeficient Mice

How to Establish Acute Myeloid Leukemia Xenograft Models Using Immunodeficient Mice

Animal models of acute myelogenous leukaemia – development, application and future perspectives

Facilitated engraftment of human hematopoietic cells in severe combined immunodeficient mice following a single injection of Cl2MDP liposomes

Contact Info

Product

Resources

About